• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nektar Therapeutics - Common Stock (NQ:NKTR)

    70.57 -0.88 (-1.23%)
    Streaming Delayed Price Updated: 3:26 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 264,680
    Open 70.84
    Bid (Size) 70.53 (200)
    Ask (Size) 70.61 (100)
    Prev. Close 71.45
    Today's Range 69.50 - 71.42
    52wk Range 21.02 - 109.00
    Shares Outstanding 183,801,441
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year ↗
    This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
    Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations. 
    Via The Motley Fool

    Performance

    YTD
    +62.5%
    +62.5%
    1 Month
    +1.1%
    +1.1%
    3 Month
    -17.0%
    -17.0%
    6 Month
    +100.3%
    +100.3%
    1 Year
    +219.8%
    +219.8%

    More News

    Read More
    News headline image
    This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
    Via The Motley Fool
    News headline image
    Nektar Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Nektar (NKTR) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
    From Rosen Law Firm
    Via Business Wire
    News headline image
    NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
    From Robbins LLP
    Via Business Wire
    News headline image
    NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
    From Bernstein Liebhard LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Nektar Therapeutics - Common Stock publicly traded?
    Yes, Nektar Therapeutics - Common Stock is publicly traded.
    What exchange does Nektar Therapeutics - Common Stock trade on?
    Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nektar Therapeutics - Common Stock?
    The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
    What is the current price of Nektar Therapeutics - Common Stock?
    The current price of Nektar Therapeutics - Common Stock is 70.57
    When was Nektar Therapeutics - Common Stock last traded?
    The last trade of Nektar Therapeutics - Common Stock was at 07/31/26 03:26 PM ET
    What is the market capitalization of Nektar Therapeutics - Common Stock?
    The market capitalization of Nektar Therapeutics - Common Stock is 12.97B
    How many shares of Nektar Therapeutics - Common Stock are outstanding?
    Nektar Therapeutics - Common Stock has 13B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.